Quel est le prix pour Altamira Therapeutics Ltd. (CYTO)

Le prix pour Altamira Therapeutics Ltd. (CYTO) est $0.3

Quelle est la capitalisation boursière pour Altamira Therapeutics Ltd. (CYTO)

La capitalisation boursière pour Altamira Therapeutics Ltd. (CYTO) est $1.13M

Bénéfices de Altamira Therapeutics Ltd. (CYTO)

Altamira Therapeutics Ltd. is a biotechnology firm dedicated to pioneering new treatments for critical medical needs that are currently underserved. Its marketed offerings include Bentrio, a non-pharmaceutical nasal spray designed for individual protection against prevalent airborne viruses and allergens. The company is also heavily invested in developing RNA therapeutics specifically for extrahepatic targets. This includes their preclinical OligoPhore and SemaPhore platforms, engineered for the effective delivery of oligonucleotides and mRNA. In its clinical-stage portfolio, AM-125 is undergoing Phase II trials for the intranasal treatment of vertigo. Additionally, Keyzilen and Sonsuvi are both in Phase III clinical development; Keyzilen is focused on acute inner ear tinnitus, and Sonsuvi addresses acute inner ear hearing loss. Established in 2003 and headquartered in Hamilton, Bermuda, Altamira Therapeutics conducts operations across Switzerland, the United States, Europe, and Australia. The company officially adopted the name Altamira Therapeutics Ltd. in July 2021, prior to which it was known as Auris Medical Holding Ltd.

Année	Bénéfices	Changez
Pas assez de données pour les dates fournies.

Année

Bénéfices

Changez

Pas assez de données pour les dates fournies.

Entreprise	Bénéfices	Différence de bénéfices	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$3.01B	-	BE

Entreprise

Bénéfices

Différence de bénéfices

Pays